Quince Therapeutics Inc
NASDAQ:QNCX
Fundamental Analysis
Revenue & Expenses Breakdown
Quince Therapeutics Inc
Balance Sheet Decomposition
Quince Therapeutics Inc
| Current Assets | 37.3m |
| Cash & Short-Term Investments | 34.7m |
| Receivables | 992k |
| Other Current Assets | 1.6m |
| Non-Current Assets | 79.9m |
| Long-Term Investments | 78k |
| PP&E | 1.1m |
| Intangibles | 67.6m |
| Other Non-Current Assets | 11.1m |
Free Cash Flow Analysis
Quince Therapeutics Inc
| USD | |
| Free Cash Flow | USD |
Earnings Waterfall
Quince Therapeutics Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-42.7m
USD
|
|
Operating Income
|
-42.7m
USD
|
|
Other Expenses
|
-6.3m
USD
|
|
Net Income
|
-49m
USD
|
QNCX Profitability Score
Profitability Due Diligence
Quince Therapeutics Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
Quince Therapeutics Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
QNCX Solvency Score
Solvency Due Diligence
Quince Therapeutics Inc's solvency score is 38/100. The higher the solvency score, the more solvent the company is.
Score
Quince Therapeutics Inc's solvency score is 38/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
QNCX Price Targets Summary
Quince Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
QNCX
is 7.65 USD
with a low forecast of 4.04 USD and a high forecast of 10.5 USD.
Dividends
Current shareholder yield for
QNCX is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?